Discovery of FLF-15 as a novel selective inhibitor of ADAM17 to prevent hepatocellular carcinoma metastasis
Molecular Diversity · 2026
DOI: 10.1007/s11030-025-11275-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Diversity, 2026. Verfasst von Qing Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, PR China. Hauptthemen laut MEDLINE: ADAM17 Protein, Liver Neoplasms, Carcinoma, Hepatocellular, Antineoplastic Agents. Die Arbeit nennt 48 Literaturangaben. Gefördert von: Natural Science Foundation of Guizhou Provincial Science and Technology Projects, National Natural Science Foundation of China, thousands of Innovative Talents of Guizhou Province.
Abstract (Originalsprache)
The poor prognosis of hepatocellular carcinoma (HCC) is mainly due to its high metastatic properties. Hence, metastasis inhibition might provide a reliable strategy for HCC treatment. As its pivotal role in the tumor cell proliferation, survival and metastasis, a disintegrin and metalloproteinase 17 (ADAM17) has become an attractive target for cancer therapy. Nevertheless, the role of ADAM17 in HCC metastasis and its underlying mechanisms remain enigmatic. In the present study, we discovered a novel ADAM17 inhibitor FLF-15, with an IC50 value of 10.43 nM. Further mechanistic studies showed that FLF-15 inhibits HCC migration and invasion in vitro and in vivo mainly by reducing interleukin-6 receptor (IL-6R) shedding, which inhibits IL-6 trans-signaling, while also leading to a reduction in IL-6 levels and downregulation of IL-6 classic-signaling. Furthermore, we revealed an overlapping but distinct biological effects of IL-6 classic and trans-signaling in HCC. Specifically, JAK2/STAT3 and ERK1/2 signaling can be stimulated by both IL-6 classic and trans-signaling pathway. However, AKT appears to be only activated by IL-6 trans-signaling pathway, suggesting its essential role for FLF-15 induced metastasis suppression in HCC. Taken together, our study identified FLF-15 as a novel ADAM17 inhibitor and elucidated its underlying mechanism of HCC metastasis suppression. These findings indicated FLF-15 might be a promising candidate for the development of HCC therapeutic agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, PR China.
- Natural Products Research Center of Guizhou Province, Guiyang, 550014, PR China.
- State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, PR China. fanyhkyem@163.com.
- Natural Products Research Center of Guizhou Province, Guiyang, 550014, PR China. fanyhkyem@163.com.
Förderung
- Natural Science Foundation of Guizhou Provincial Science and Technology Projects
- National Natural Science Foundation of China
- thousands of Innovative Talents of Guizhou Province
- Science and Technology Plan Project of Guizhou Province
Zitieren
APA
Li, Q., Wang, D. P., Zhong, T., Ling-Hu, A. L., Chen, J. L., Luo, F., Zhang, F., Su, M. Z., Yang, Y., & Fan, Y. H. (2026). Discovery of FLF-15 as a novel selective inhibitor of ADAM17 to prevent hepatocellular carcinoma metastasis. Molecular Diversity. https://doi.org/10.1007/s11030-025-11275-7
Vancouver
Li Q, Wang DP, Zhong T, Ling-Hu AL, Chen JL, Luo F, et al. Discovery of FLF-15 as a novel selective inhibitor of ADAM17 to prevent hepatocellular carcinoma metastasis. Molecular Diversity. 2026. doi:10.1007/s11030-025-11275-7
BibTeX
@article{Li2026,
author = {Li, Qing and Wang, Dao-Ping and Zhong, Ting and Ling-Hu, Ai-Ling and Chen, Jia-Lin and Luo, Fang and Zhang, Feng and Su, Ming-Zhi and Yang, Ying and Fan, Yan-Hua},
title = {Discovery of FLF-15 as a novel selective inhibitor of ADAM17 to prevent hepatocellular carcinoma metastasis},
journal = {Molecular Diversity},
year = {2026},
doi = {10.1007/s11030-025-11275-7}
}
EUVIMED